Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma

被引：18

作者：

Minami, Tatsuya ^{[1
]}

Tateishi, Ryosuke ^{[1
]}

Shiina, Shuichiro ^{[2
]}

Nakagomi, Ryo ^{[1
]}

Kondo, Mayuko ^{[1
]}

Fujiwara, Naoto ^{[1
]}

Mikami, Shintaro ^{[1
]}

Sato, Masaya ^{[1
]}

Uchino, Koji ^{[1
]}

Enooku, Kenichiro ^{[1
]}

Nakagawa, Hayato ^{[1
]}

Asaoka, Yoshinari ^{[1
]}

Kondo, Yuji ^{[1
]}

Yoshida, Haruhiko ^{[1
]}

Koike, Kazuhiko ^{[1
]}

机构：

[1] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo 1138655, Japan

[2] Juntendo Univ, Dept Gastroenterol, Tokyo, Japan

来源：

HEPATOLOGY RESEARCH | 2015年 / 45卷 / 10期

关键词：

hepatitis C; hepatitis B; hepatocellular carcinoma; nucleoside; nucleotide analogs; prognosis; PERCUTANEOUS RADIOFREQUENCY ABLATION; ANTIVIRAL THERAPY; LIVER-TRANSPLANTATION; INTERFERON THERAPY; TUMOR ABLATION; RISK-FACTORS; RECURRENCE; LAMIVUDINE; CIRRHOSIS; EFFICACY;

D O I：

10.1111/hepr.12468

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

AimTreatment strategies for hepatocellular carcinoma (HCC) have been advanced. The aim of this study was to compare the change of the prognosis between hepatitis B-related HCC (B-HCC) and hepatitis C-related HCC (C-HCC) in the last two decades. MethodsWe enrolled 166 B-HCC patients who underwent percutaneous ablation between 1990 and 2009. Patients were divided into three groups according to the treatment time period: 1990-1995 (cohort 1, n=19), 1996-2002 (cohort 2, n=49) and 2003-2009 (cohort 3, n=98). We enrolled 1219 C-HCC patients who underwent percutaneous ablation during the same period (n=190, 413 and 616, respectively.). Interferon and nucleoside/nucleotide analog use was investigated. Prognosis was evaluated for each cohort using the Kaplan-Meier method and a multivariate Cox proportional hazard regression model. ResultsTwo (11%), 24 (49%) and 80 (82%) B-HCC patients received nucleoside/nucleotide analogs during the follow-up period in cohorts 1-3, respectively. Among them 1, 18 and 62 patients achieved viral remission, respectively. Thirty-four (18%), 35 (8%) and 84 (14%) C-HCC patients received interferon therapy, respectively. The 5-year B-HCC (P<0.001) survival rates were 52.6%, 61.1% and 81.6% for cohorts 1-3, respectively. However, the survival rates were 55.6%, 58.8% and 61.1% for C-HCC (P=0.12), respectively. The B-HCC prognosis improved dramatically (P<0.001) over time, whereas the prognosis of C-HCC improved moderately (P=0.01). ConclusionThe prognosis of B-HCC has improved dramatically over time, whereas that of C-HCC has improved moderately.

引用

页码：E99 / E107

页数：9